Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000503:physiopathology*; D004569:Electroencephalography; D004921:Erythropoietin / Q000627:therapeutic use*; D005221:Fatigue; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000523:psychology* / Q000534:rehabilitation; D009483:Neuropsychological Tests; D018579:Patient Selection; D011788:Quality of Life; D011994:Recombinant Proteins; D011795:Surveys and Questionnaires
D011994:Recombinant Proteins; D004921:Erythropoietin